Randomization
atrial fibrillation, Universität Leipzig
ATRIAL FIBRILLATION, TYPE 2 DIABETES
Patients were randomized (1:1) to mirabegron (50 mg/d) or placebo, stratified by the presence or absence of type 2 diabetes and atrial fibrillation at randomization. This dosage was chosen on the basis of safety data from previous clinical trials, as allowed by ethics committees in all participating countries. Allocation concealment and randomization were ensured centrally through a secure web-based tool held by Universität Leipzig using a modified minimization procedure with a stochastic component, according to Pocock and Simon.